Last reviewed · How we verify

Sangart — Portfolio Competitive Intelligence Brief

Sangart pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hemospan (MP4OX) Hemospan (MP4OX) phase 3 Hemoglobin-based oxygen carrier Hemoglobin (oxygen binding and transport) Hematology / Critical Care / Trauma
Voluven (HES 130/0.4) Voluven (HES 130/0.4) phase 3 Colloid volume expander Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Asian Institute of Gastroenterology, India · 1 shared drug class
  2. Insel Gruppe AG, University Hospital Bern · 1 shared drug class
  3. Rennes University Hospital · 1 shared drug class
  4. The University of Texas Health Science Center, Houston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sangart:

Cite this brief

Drug Landscape (2026). Sangart — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sangart. Accessed 2026-05-13.

Related